Home Companies Catalysts Deep Dives
Bomedemstat MK-3543 PHASE3
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Peak Sales Est$1500M
Formulations[]
Companies
MRK (ORIGINATOR)100%
Mechanism: LSD1 inhibitor
Expert: Lysine-specific demethylase 1 inhibitor
Everyday: Blocks enzyme that helps blood cancers grow
Targets: ["LSD1"]
Programs (1)
IndicationStageKey StudyRegional Status
MyelofibrosisPHASE3BOMEDEST-MF[]
Notes
LSD1 inhibitor for myelofibrosis and essential thrombocythemia. Acquired via Imago.
Data from Supabase · Updated 2026-03-24